Evotec slumps on 2026 outlook falling short of expectations

Evotec SE

10/03/2026 09:50

** German drug discovery firm Evotec EVTG.DE shares fall 11% after its 2026 outlook falls short of expectations

** Evotec expects 2026 adjusted EBITDA of around 0-40 million euros ($0-46 million), falling below analysts' expectations of 78 million euros, cited by RBC

** "We do not understand the reason for the projected margin decline," RBC says

** The broker adds the guidance is a near-term negative that is likely to be of the greatest focus for investors

** Evotec's stock is on track to reach its lowest level since early November 2016

($1 = 0.8584 euros)

(Reporting by Tristan Veyet)

((Tristan.veyet@thomsonreuters.com))